AR111374A1 - USE OF LIK066 IN PATIENTS WITH HEART FAILURE - Google Patents

USE OF LIK066 IN PATIENTS WITH HEART FAILURE

Info

Publication number
AR111374A1
AR111374A1 ARP180100910A ARP180100910A AR111374A1 AR 111374 A1 AR111374 A1 AR 111374A1 AR P180100910 A ARP180100910 A AR P180100910A AR P180100910 A ARP180100910 A AR P180100910A AR 111374 A1 AR111374 A1 AR 111374A1
Authority
AR
Argentina
Prior art keywords
lik066
heart failure
patients
subject
treatment
Prior art date
Application number
ARP180100910A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR111374A1 publication Critical patent/AR111374A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Reivindicación 1: Un método para el tratamiento o la prevención de la insuficiencia cardíaca en un sujeto que necesite dicho tratamiento, que comprende administrar a dicho sujeto una cantidad terapéuticamente eficaz de LIK066, o de una de sus sales farmacéuticamente aceptables.Claim 1: A method for the treatment or prevention of heart failure in a subject in need of said treatment, comprising administering to said subject a therapeutically effective amount of LIK066, or of a pharmaceutically acceptable salt thereof.

ARP180100910A 2017-04-12 2018-04-11 USE OF LIK066 IN PATIENTS WITH HEART FAILURE AR111374A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762484497P 2017-04-12 2017-04-12

Publications (1)

Publication Number Publication Date
AR111374A1 true AR111374A1 (en) 2019-07-03

Family

ID=62116505

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100910A AR111374A1 (en) 2017-04-12 2018-04-11 USE OF LIK066 IN PATIENTS WITH HEART FAILURE

Country Status (4)

Country Link
JP (1) JP2019517459A (en)
AR (1) AR111374A1 (en)
TW (1) TW201841643A (en)
WO (1) WO2018189671A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638362B1 (en) 2017-06-16 2021-07-21 Cardiac Pacemakers, Inc. Dynamic control of heart failure therapy
WO2020123487A1 (en) 2018-12-11 2020-06-18 Cardiac Pacemakers, Inc. Hfpef detection using exertional heart sounds
US11311731B2 (en) 2019-04-12 2022-04-26 Cardiac Pacemakers, Inc. Cardiac resynchronization therapy heart sound response characterization
US11318313B2 (en) 2019-04-12 2022-05-03 Cardiac Pacemakers, Inc. Response-based cardiac resynchronization therapy parameter determination
EP4003368A1 (en) * 2019-07-23 2022-06-01 Novartis AG Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
CN114304880B (en) * 2021-12-28 2023-05-26 圣奥科技股份有限公司 Lifting table standing position height recommendation method for healthy office

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2997966A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
WO2016198628A1 (en) * 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists

Also Published As

Publication number Publication date
WO2018189671A1 (en) 2018-10-18
JP2019517459A (en) 2019-06-24
TW201841643A (en) 2018-12-01

Similar Documents

Publication Publication Date Title
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
AR126205A2 (en) METHODS OF USE OF TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE REFRACTORY MELANOMA
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
DOP2017000272A (en) METHODS OF DIAGNOSIS FOR TREATMENT WITH LYMPHOCYTES T
CL2020002512A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors.
CO2018006358A2 (en) Treatment of fabry disease in patients not treated and previously treated with ert
CL2016001756A1 (en) Pharmaceutical preparation comprising 0.001-0.003 pv of 6-4-pyrazol-1-ylbenzylpyridin-3-ylsulfonylaminomethylpyridin-2-ylaminoacetate isopropyl or a salt of the same use for the treatment or prevention of glaucoma or ocular hypertension.
AR102973A1 (en) USE OF THE 3,5-DIHIDROXI-4-ISOPROPIL-TRANS-ESTILBENE COMPOUND FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, SUCH COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR112144A1 (en) COMPOUNDS FOR THE TREATMENT OF SARCOMA
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
CL2020000491A1 (en) Methods to increase and / or stabilize cardiac function in patients with Fabry disease.
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
CL2021000030A1 (en) Use of sgc stimulators for the treatment of mitochondrial disorders
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
CO2022004947A2 (en) Dosage regimens for the treatment of patients with locally advanced squamous cell carcinoma
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
AR111699A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING BETAHISTINA
AR103636A1 (en) METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND
ZA202006986B (en) Dantrolene formulations and methods of their use

Legal Events

Date Code Title Description
FB Suspension of granting procedure